Fusogenics™ is Viventia’s unique immune system-driven discovery platform. Fusogenics™ leverages the human immune response to cancer to discover antibodies that selectively target cancer cells.

The human immune response to cancer can be exploited as a powerful and unique method to both discover novel tumor antigens and to generate human monoclonal antibodies in the development of potent cancer therapeutics.